[go: up one dir, main page]

MX2009012390A - Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes. - Google Patents

Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.

Info

Publication number
MX2009012390A
MX2009012390A MX2009012390A MX2009012390A MX2009012390A MX 2009012390 A MX2009012390 A MX 2009012390A MX 2009012390 A MX2009012390 A MX 2009012390A MX 2009012390 A MX2009012390 A MX 2009012390A MX 2009012390 A MX2009012390 A MX 2009012390A
Authority
MX
Mexico
Prior art keywords
pyrrolidin
clinically latent
latent microorganisms
quinoline compounds
compounds
Prior art date
Application number
MX2009012390A
Other languages
English (en)
Inventor
Mandy Christine Beswick
Susan Mary Cramp
Yanmin Hu
Thomas David Pallin
Hazel Joan Dyke
Anthony Coates
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709489A external-priority patent/GB0709489D0/en
Priority claimed from GB0807591A external-priority patent/GB0807591D0/en
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of MX2009012390A publication Critical patent/MX2009012390A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona el uso de compuestos de la fórmula en donde R1, R2, R3 y E tienen los significados proporcionados en la descripción, para la preparación de un medicamento para exterminar microorganismos clínicamente latentes. También se proporciona el uso de compuestos de la fórmula I para tratar infecciones microbianas, así como ciertos compuesto de la fórmula (I) per se.
MX2009012390A 2007-05-17 2008-05-16 Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes. MX2009012390A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0709489A GB0709489D0 (en) 2007-05-17 2007-05-17 New use
GB0807591A GB0807591D0 (en) 2008-04-25 2008-04-25 New use
PCT/GB2008/001694 WO2008142384A1 (en) 2007-05-17 2008-05-16 Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms

Publications (1)

Publication Number Publication Date
MX2009012390A true MX2009012390A (es) 2010-06-23

Family

ID=39672613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012390A MX2009012390A (es) 2007-05-17 2008-05-16 Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.

Country Status (20)

Country Link
US (1) US8759348B2 (es)
EP (1) EP2182950B8 (es)
JP (1) JP5474768B2 (es)
KR (1) KR101599384B1 (es)
CN (1) CN101795688B (es)
AU (1) AU2008252636B2 (es)
BR (1) BRPI0811745B1 (es)
CA (1) CA2684692C (es)
DK (1) DK2182950T3 (es)
ES (1) ES2637999T3 (es)
HR (1) HRP20171553T1 (es)
HU (1) HUE034298T2 (es)
IL (1) IL201392A (es)
MX (1) MX2009012390A (es)
NZ (1) NZ580625A (es)
PL (1) PL2182950T3 (es)
PT (1) PT2182950T (es)
RU (1) RU2520766C2 (es)
SI (1) SI2182950T1 (es)
WO (1) WO2008142384A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095522A (ja) * 2008-09-19 2010-04-30 Sumitomo Chemical Co Ltd 植物病原菌による植物病害を防除又は予防するための農業用組成物
PT2552440T (pt) * 2010-03-30 2019-01-10 Helperby Therapeutics Ltd Nova combinação e uso
WO2011143495A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
GB201013207D0 (en) 2010-08-05 2010-09-22 Helperby Therapeutics Ltd Novel combination
EP2600869B1 (en) 2010-08-05 2020-09-23 Helperby Therapeutics Limited Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
EP3283178A1 (en) 2015-04-11 2018-02-21 Helperby Therapeutics Limited Oral composition
US10329257B2 (en) 2015-08-13 2019-06-25 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
GB201518969D0 (en) 2015-10-27 2015-12-09 Helperby Therapeutics Ltd Triple combination
WO2017120225A1 (en) * 2016-01-04 2017-07-13 The Johns Hopkins University Use of low dose emetine for inhibition of human cytomegalovirus (hcmv)
KR102665309B1 (ko) * 2016-10-27 2024-05-10 주식회사 엘지생활건강 코디세핀을 포함하는 구강질환 예방 또는 치료용 조성물
GB201703898D0 (en) 2017-03-10 2017-04-26 Helperby Therapeautics Ltd Method
RU2664177C1 (ru) * 2017-08-07 2018-08-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ лечения абсцедирующих фурункулов верхней и нижней зон лица
WO2019036657A1 (en) * 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
EP3727382A4 (en) * 2017-12-18 2021-09-08 Ansella Therapeutics, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES
CN110897032B (zh) * 2019-11-19 2025-10-14 华南理工大学 一种发酵饲料蛋白及其制备方法与应用
RU2758056C2 (ru) * 2019-11-21 2021-10-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат для лечения отитов бактериальной и грибковой этиологии у собак
CN111544599B (zh) * 2020-07-10 2020-12-01 有术肌肤管理(深圳)有限公司 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途
KR102461715B1 (ko) * 2020-10-12 2022-11-02 대한민국 항균 및 항진균 활성을 나타내는 신균주 페니실리움 비세티 및 이의 용도
CN114831924A (zh) * 2021-03-17 2022-08-02 武汉恒信源药业有限公司 一种乌洛托品及其化合物的阴道局部给药制剂及用途
CN113528388A (zh) * 2021-07-19 2021-10-22 海南大学 珊瑚共生链霉菌、发酵生产放线菌素d的方法及应用
KR20240144096A (ko) 2021-11-02 2024-10-02 플레어 테라퓨틱스 인크. Pparg 역 효능제 및 그의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
DE60227794D1 (de) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
CN100376557C (zh) * 2001-05-21 2008-03-26 霍夫曼-拉罗奇有限公司 作为神经肽y受体的配体的喹啉衍生物
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
EP1451156A4 (en) * 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
RU2298002C2 (ru) * 2002-02-04 2007-04-27 Ф. Хоффманн-Ля Рош Аг Производные хинолина в качестве антагонистов npy
JP2005537247A (ja) 2002-06-27 2005-12-08 シエーリング アクチエンゲゼルシャフト 置換されたキノリンｃｃｒ５受容体アンタゴニスト
RU2343946C2 (ru) * 2002-08-19 2009-01-20 Ави ЭЛЬБАЗ Проприоцептивное/кинестетическое устройство и способ
US7223776B2 (en) * 2002-10-10 2007-05-29 Morphochem Ag Compounds with anti-bacterial activity
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
GB0522715D0 (en) * 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use

Also Published As

Publication number Publication date
JP5474768B2 (ja) 2014-04-16
IL201392A (en) 2016-03-31
WO2008142384A1 (en) 2008-11-27
NZ580625A (en) 2011-12-22
PT2182950T (pt) 2017-09-11
CN101795688A (zh) 2010-08-04
KR101599384B1 (ko) 2016-03-03
DK2182950T3 (da) 2017-11-06
RU2520766C2 (ru) 2014-06-27
CA2684692C (en) 2016-07-05
RU2009146828A (ru) 2011-06-27
CN101795688B (zh) 2015-05-20
KR20100021476A (ko) 2010-02-24
CA2684692A1 (en) 2008-11-27
US8759348B2 (en) 2014-06-24
HUE034298T2 (en) 2018-02-28
HRP20171553T1 (hr) 2017-12-15
AU2008252636A1 (en) 2008-11-27
IL201392A0 (en) 2010-05-31
EP2182950B8 (en) 2017-08-23
PL2182950T3 (pl) 2018-01-31
BRPI0811745B1 (pt) 2019-06-04
US20100305065A1 (en) 2010-12-02
JP2010527346A (ja) 2010-08-12
SI2182950T1 (en) 2018-01-31
ES2637999T3 (es) 2017-10-18
EP2182950B1 (en) 2017-07-19
BRPI0811745A2 (pt) 2014-11-11
EP2182950A1 (en) 2010-05-12
AU2008252636B2 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
MX2009012390A (es) Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
NZ593111A (en) Antibacterial compounds
NZ601121A (en) 5-alkynyl-pyrimidines
GEP20166443B (en) Heterocyclic compound and use thereof
MY155517A (en) Heterocyclic derivatives
MX2010008921A (es) Derivados de oxazolidinona.
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
EA200901187A1 (ru) Диаминопиримидины в качестве фунгицидов
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
GEP20135983B (en) 1-benzyl-3-hydroxymethylindazole derivatives and usage therein treatment of diseases based on mcp-1, cx3cr1 and p40 expression
MX2010009922A (es) Activadores de piridazinona glucocinasa.
TW200716628A (en) Novel compounds
SE0401342D0 (sv) Therapeutic compounds
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
EA201100872A1 (ru) Производные хиназолинамида
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
SE0401969D0 (sv) Piperidine derivatives

Legal Events

Date Code Title Description
FG Grant or registration